P. Foley1, M. Walsh2, E. Mate2
Introduction: Secukinumab (SEC) is a fully human monoclonal antibody that selectively neutralises interleukin 17A and has shown sustained efficacy with a favourable safety profile in psoriasis, psoriatic arthritis and ankylosing spondylitis. SEC treatment has also provided fast and persistent improvements in quality of life for patients with moderate to severe psoriasis in the clinical trial setting. Here we describe the design and results of HOPE, a trial investigating quality of life in patients treated with SEC in real world Australian clinical practice.
Objectives: The primary aim of this study was to demonstrate the change in patient-reported outcomes using the Dermatology Quality of Life Index (DLQI) and Assessment Quality of Life (AQoL-8D) tool in patients treated with SEC for moderate to severe chronic plaque psoriasis.
Methods: HOPE study is a prospective, open label, single arm, multi-centre, non-interventional, exploratory trial in patients with moderate to severe psoriasis, investigating their change in quality of life in response to treatment with SEC. Secukinumab was administered as 300 mg s.c. weekly for 4 weeks followed by monthly maintenance (commencing at week 4) over 58 weeks in accordance with the approved Australian prescribing label. The study recruited adult subjects who presented with moderate to severe chronic plaque psoriasis and who were eligible for PBS reimbursed SEC.
Conclusion: This is the first prospective, non-interventional real world study assessing change in quality of life in response to treatment with secukinumab in the local Australian clinical setting.